Cristian Merino

Cristian Merino

Auto-generated profile, based on publicly available information

Cristian Merino

Centro de Química Médica, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago 7780272, Chile, Chile

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Jackson J. AlcázarJackson J. Alcázar
Jackson J. Alcázar
ISIgnacio Sánchez
Ignacio Sánchez
CMCristian Merino
Cristian Merino
BMBruno Monasterio
Bruno Monasterio
GSGaspar Sajuria
Gaspar Sajuria
PCPaola R. Campodónico
Paola R. Campodónico
Background/Objectives: Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly in cases driven by mutations in the FLT3 tyrosine kinase. This study aimed to develop a robust and user-friendly machine learning-based quantitative structure–activity relationship (QSAR) model to predict the inhibitory potency (pIC50 values) of FLT3 inhibitors, addressing the limitations of previous models in dataset size, diversity, and predictive accuracy. Methods: Using a dataset which was 14 times larger than those employed in prior studies (1350 compounds with 1269 molecular descriptors), we trained a random forest regressor, chosen due to its superior predictive performance and resistance to overfitting. Rigorous internal validation via leave-one-out and 10-fold cross-validation yielded Q2 values of 0.926 and 0.922, respectively, while external validation on 270 independent compounds resulted in an R2 value of 0.941 with a standard deviation of 0.237. Results: Key molecular descriptors influencing the inhibitor potency were identified, thereby improving the interpretability of structural requirements. Additionally, a user-friendly computational tool was developed to enable rapid prediction of pIC50 values and facilitate ligand-based virtual screening, leading to the identification of promising FLT3 inhibitors. Conclusions: These results represent a significant advancement in the field of FLT3 inhibitor discovery, offering a reliable, practical, and efficient approach for early-stage drug development, potentially accelerating the creation of targeted therapies for AML.

17 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Jackson J. AlcázarJackson J. Alcázar
Jackson J. Alcázar
ISIgnacio Sánchez
Ignacio Sánchez
CMCristian Merino
Cristian Merino
BMBruno Monasterio
Bruno Monasterio
GSGaspar Sajuria
Gaspar Sajuria
PCPaola R. Campodónico
Paola R. Campodónico
In this study, a simple machine learning-based quantitative structure-activity relationship (QSAR) model has been developed to predict the inhibitory potency (pIC50 values) of FLT3 tyrosine kinase inhibitors, crucial for the treatment of acute myeloid leukemia. Distinctively, our model leverages an extensive and diverse dataset, 14 times larger than those employed in prior studies within this field, enabling an unparalleled scope of compound analysis. This vast dataset, combined with further exploration of molecular descriptors, allows for more accurate and efficient predictions than previous studies. The Random Forest Regressor algorithm, selected for its excellent predictive performance, was trained on a dataset comprising 1080 compounds and subjected to rigorous validation. Internal validation, performed through Leave-One-Out (LOO) cross-validation, yielded an Q2LOO value of 0.92, demonstrating the model's internal consistency and predictive reliability. Additionally, external validation using 270 independent compounds not included in the training set achieved an R2 of 0.941, with a standard deviation of 0.237, outperforming previous approaches in terms of simplicity and precision. Key molecular descriptors have been identified, enhancing the understanding of structural requirements for inhibitor potency. Additionally, a user-friendly computational tool has been developed, enabling rapid predictions of pIC50 values. Using this tool, potential FLT3 inhibitors have been identified via ligand-based virtual screening. This study represents a significant advancement in FLT3 inhibitor discovery using a simplified QSAR-machine learning model, enabling more precise and practical identification of potential drug candidates at an early stage, promising faster development of targeted therapies and streamlining the ligand-based drug design process.